Literature DB >> 23430665

Omega-3 in antiarrhythmic therapy : cons position.

Claudio Borghi1, Ilenia Pareo.   

Abstract

The association between omega-3 (n-3 polyunsaturated fatty acids) and the clinical outcome of patients with cardiovascular diseases such as coronary heart disease is currently unclear, especially regarding its possible antiarrhythmic effects and the not quite understood mechanisms of action. In the last 15 years, several epidemiological studies have shown a lower incidence of sudden cardiac death with a diet rich in omega-3 or fish consumption. The antiarrhythmic properties related to omega-3 have been related to modulation of sodium-dependent ion channels or sodium-calcium exchangers of myocytes through a reduction of their excitability especially in ischaemic or damaged myocardial tissue. However, the results of experimental studies have not always been consistent. Although the role of omega-3 in preventing sudden cardiac death has been evaluated in several clinical trials that included patients with coronary artery disease (particularly in patients with post-myocardial infarction), the interpretation of such data must be treated with extreme caution. In particular, while a reduction in cardiac death was demonstrated by a meta-analysis of several randomized clinical trials, a reduced risk of sudden cardiac death has been described only in the GISSI-Prevenzione study, while in other studies the evidence that emerged is more controversial, with wide confidence intervals that support the possibility of heterogeneity in the distribution of the factors involved in the efficacy of treatment. Omega-3 is probably involved in the prevention of cardiovascular mortality through different mechanisms, and it is crucial to study its association with other drugs such as ACE inhibitors or calcium channel blockers. The study of antiarrhythmic drugs has been divided into prevention of supraventricular and ventricular arrhythmias. In these conditions, the role of omega-3 seems to be more pronounced in atrial tachyarrhythmias such as atrial fibrillation, but does not have a role in ventricular arrhythmias. In summary, the antiarrhythmic effect of omega-3 is not clearly evident and further studies are needed to investigate its beneficial effect in cardiac mortality compared with arrhythmic death.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23430665     DOI: 10.1007/BF03297632

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  22 in total

Review 1.  Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.

Authors:  Irene Savelieva; Nicholaos Kakouros; Antonios Kourliouros; A John Camm
Journal:  Europace       Date:  2011-03       Impact factor: 5.214

Review 2.  Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events.

Authors:  Dariush Mozaffarian; Jason H Y Wu
Journal:  J Am Coll Cardiol       Date:  2011-11-08       Impact factor: 24.094

3.  Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial.

Authors:  Merritt H Raitt; William E Connor; Cynthia Morris; Jack Kron; Blair Halperin; Sumeet S Chugh; James McClelland; James Cook; Karen MacMurdy; Robert Swenson; Sonja L Connor; Glenn Gerhard; Dale F Kraemer; Daniel Oseran; Christy Marchant; David Calhoun; Reed Shnider; John McAnulty
Journal:  JAMA       Date:  2005-06-15       Impact factor: 56.272

Review 4.  Evidence-based medicine and ACE inhibition.

Authors:  C Borghi; E Ambrosioni
Journal:  J Cardiovasc Pharmacol       Date:  1998       Impact factor: 3.105

5.  n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study.

Authors:  Savina Nodari; Marco Triggiani; Umberto Campia; Alessandra Manerba; Giuseppe Milesi; Bruno M Cesana; Mihai Gheorghiade; Livio Dei Cas
Journal:  Circulation       Date:  2011-08-15       Impact factor: 29.690

6.  N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial.

Authors:  Leonardo Calò; Leopoldo Bianconi; Furio Colivicchi; Filippo Lamberti; Maria Luisa Loricchio; Ermenegildo de Ruvo; Antonella Meo; Claudio Pandozi; Mario Staibano; Massimo Santini
Journal:  J Am Coll Cardiol       Date:  2005-05-17       Impact factor: 24.094

7.  Blood levels of long-chain n-3 fatty acids and the risk of sudden death.

Authors:  Christine M Albert; Hannia Campos; Meir J Stampfer; Paul M Ridker; JoAnn E Manson; Walter C Willett; Jing Ma
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

8.  OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.

Authors:  Bernhard Rauch; Rudolf Schiele; Steffen Schneider; Frank Diller; Norbert Victor; Helmut Gohlke; Martin Gottwik; Gerhard Steinbeck; Ulrike Del Castillo; Rudolf Sack; Heinrich Worth; Hugo Katus; Wilhelm Spitzer; Georg Sabin; Jochen Senges
Journal:  Circulation       Date:  2010-11-08       Impact factor: 29.690

Review 9.  Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance.

Authors:  Irene Savelieva; Antonios Kourliouros; John Camm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11-25       Impact factor: 3.000

10.  Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest.

Authors:  D S Siscovick; T E Raghunathan; I King; S Weinmann; K G Wicklund; J Albright; V Bovbjerg; P Arbogast; H Smith; L H Kushi
Journal:  JAMA       Date:  1995-11-01       Impact factor: 56.272

View more
  3 in total

Review 1.  Omega-3 fatty acids: a growing ocean of choices.

Authors:  Hassan Fares; Carl J Lavie; James J DiNicolantonio; James H O'Keefe; Richard V Milani
Journal:  Curr Atheroscler Rep       Date:  2014-02       Impact factor: 5.113

Review 2.  Omega-3 Index and Anti-Arrhythmic Potential of Omega-3 PUFAs.

Authors:  Narcis Tribulova; Barbara Szeiffova Bacova; Tamara Egan Benova; Vladimir Knezl; Miroslav Barancik; Jan Slezak
Journal:  Nutrients       Date:  2017-10-30       Impact factor: 5.717

Review 3.  Mechanisms Underlying Antiarrhythmic Properties of Cardioprotective Agents Impacting Inflammation and Oxidative Stress.

Authors:  Katarina Andelova; Barbara Szeiffova Bacova; Matus Sykora; Peter Hlivak; Miroslav Barancik; Narcis Tribulova
Journal:  Int J Mol Sci       Date:  2022-01-26       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.